Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...